Form4insider filings, from the source

SEC Form 4 · accession 0001193805-15-000970

ANTARES PHARMA, INC. · ATRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, LP
10% Owner · Other
James E Flynn
10% Owner · Other
Period of report
Jun 11, 2015
Accepted (ET)
Jun 15, 2015 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jun 11, 2015S24,612$2.4797D3,882,954IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 11, 2015S28,574$2.4662D3,854,380IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 11, 2015S74,137$2.4797D9,821,484IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 11, 2015S58,251$2.4797D7,716,880IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 11, 2015S86,071$2.4662D9,735,413IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 11, 2015S67,627$2.4662D7,649,253IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 12, 2015S7,838$2.425D3,846,542IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 12, 2015S7,838$2.425D3,838,704IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 12, 2015S18,595$2.4284D3,820,109IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 12, 2015S23,611$2.425D9,711,802IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 12, 2015S18,551$2.425D7,630,702IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 12, 2015S23,611$2.425D9,688,191IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 12, 2015S18,551$2.425D7,612,151IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 12, 2015S56,012$2.4284D9,632,179IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 12, 2015S44,010$2.4284D7,568,141IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 15, 2015S4,722$2.405D9,627,457IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 15, 2015S3,710$2.405D7,564,431IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 15, 2015S15,866$2.40D9,611,591IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 15, 2015S12,467$2.40D7,551,964IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 15, 2015S69,198$2.4004D9,542,393IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 15, 2015S54,370$2.4004D7,497,594IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 15, 2015S1,568$2.405D3,818,541IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 15, 2015S5,267$2.40D3,813,274IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 15, 2015S22,973$2.4004D3,790,301IThrough Deerfield Special Situations Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.